AURA — Aura Biosciences, Inc.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for AURA in the TickerWise workspace.

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 106
• Website: https://www.aurabiosciences.com

Latest SEC filings for AURA

• 2026-09-01S-8
• 2026-08-21EFFECT
• 2026-08-11S-3
• 2026-08-118-K
• 2026-08-1110-Q
• 2026-08-058-K
• 2026-07-088-K
• 2026-06-118-K
• 2026-05-11SCHEDULE 13D/A
• 2026-05-1110-Q

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.